DUBLIN--(BUSINESS WIRE)--The "Hospital Acquired Disease Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023" report has been added to ResearchAndMarkets.com's offering.
The global hospital acquired disease testing market was worth US$ 752 Million in 2017
The market for hospital acquired disease testing is currently exhibiting double digit growth rates. Catalyzed by a rising population and the modernization of the healthcare infrastructure, there has been a significant increase in the number of health care facilities across the globe. This has resulted in a rising incidence of HAIs, driving the demand of hospital acquired disease tests.
Moreover, with advanced technologies and scientific innovations, various techniques are now available in the market for preventing, diagnosing, and monitoring HAIs such as microarrays, polymerase chain reaction (PCR), real time location systems (RTLSs), and solid phase hybridization.
Techniques such as RTLS makes it easy to prevent HAIs from spreading in both patients and staff. Growing awareness of HAIs among patients and governments enacting regulations that penalize hospitals having a high incidence of HAIs are some of the other factors that are catalyzing the growth of the market.
Looking forward, the market value is projected to exceed US$ 1,720 Million by 2023, exhibiting a CAGR of around 18% during 2018-2023.
Key Topics Covered:
2 Scope and Methodology
3 Executive Summary
5 Global Hospital Acquired Disease Testing Market
6 Market Breakup by Indication
7 Market Breakup by Region
8 Competitive Landscape
- Abbott Laboratories
- Alere Inc.
- bioMrieux SA
- F. Hoffmann-La Roche Ltd.
- Hologic Inc.
- Siemens Healthcare
- Diatherix Laboratories Inc.
- Meridian Bioscience Inc.
- Thermo Fisher Scientific Inc. (Life Technologies Corporation)
- Cepheid Inc.
For more information about this report visit https://www.researchandmarkets.com/research/mzd28b/global_hospital?w=4